Mogenry (sonpiretigene isteparvovec, MCO-010) for Retinitis pigmentosa with severe vision loss
The FDA is expected to decide on Mogenry for Retinitis pigmentosa with severe vision loss in an undisclosed window, under a BLA from Nanoscope Therapeutics.
What is being decided
Nanoscope Therapeutics has a BLA under FDA review for Mogenry (sonpiretigene isteparvovec, MCO-010) in Retinitis pigmentosa with severe vision loss. One-time in-office injection that makes surviving retinal cells light-sensitive, so it works regardless of which gene caused the disease. The FDA accepted the application on September 9, 2026; Nanoscope has not disclosed a target action date.
Who this decision matters to
Retinitis pigmentosa is a group of inherited retinal dystrophies causing progressive degeneration of the photoreceptor layer of the eye. Patients experience night blindness, progressive peripheral vision loss, and eventual central vision loss. Voretigene neparvovec (Luxturna) is FDA-approved for RPE65-associated retinal dystrophy, which includes some RP patients, though most RP subtypes still lack approved therapies.
Prevalence: Approximately 1 in 4,000 people worldwide. See our full Retinitis Pigmentosa page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Retinitis Pigmentosa treatment stands today
Gene therapy development is accelerating rapidly for retinitis pigmentosa, with multiple trials now actively recruiting qualified participants. Initial approaches target specific gene mutations known to cause RP, particularly X-linked and autosomal recessive forms where gene replacement has shown promise. Genetic testing identifying your specific RP mutation is essential, as newer trials are mutation-specific and can only be accessed by patients carrying appropriate mutations. Nutritional interventions including vitamin A supplementation and monitoring remain important elements of supportive care for maintaining retinal function. The American Academy of Ophthalmology and Foundation Fighting Blindness maintain comprehensive trial registries updated regularly. Nutrition counseling from specialists familiar with RP can optimize supplementation strategies. Work with a retinal specialist experienced in inherited dystrophies who can order comprehensive genetic testing, monitor disease progression precisely, and identify trial opportunities aligned specifically with your genetic subtype.
Meanwhile, 67 Retinitis Pigmentosa trials are recruiting
Whatever the FDA decides here, research on Retinitis Pigmentosa does not stop. A few currently enrolling studies, US sites first:
Get notified when new retinitis-pigmentosa trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Mogenry?
Nanoscope Therapeutics has disclosed a decision window of later this cycle for Mogenry in Retinitis pigmentosa with severe vision loss, without an exact date.
What is Mogenry being reviewed for?
Nanoscope Therapeutics submitted a BLA for Mogenry in Retinitis pigmentosa with severe vision loss. One-time in-office injection that makes surviving retinal cells light-sensitive, so it works regardless of which gene caused the disease. The FDA accepted the application on September 9, 2026; Nanoscope has not disclosed a target action date.
What happens after the Mogenry decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Nanoscope press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified weekly.